Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1623 other investors.
Redeye returns with an updated take on the pick-and-shovel play Genovis following its partner Selecta Biosciences’ licensing deal with Astellas Pharma and the company’s Q4 2022 report. With reinforced confidence in the deal with Selecta, we have raised our base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
The strong growth in the core business during the fourth quarter continues in the beginning of 2023
Today Selecta Biosciences announced the sublicensing of the Xork enzyme to Astellas Pharma for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease.
Redeye returns with an updated take on the pick-and-shovel play Genovis following a site visit and change of lead analyst.
Redeye leaves a more elaborate take on Genovis following its Q3 2022 report. We are left with a positive bias after yesterday's report and make minor adjustments to our forecasts, resulting in an updated fair value range.
Redeye provides its initial take on Genovis’ Q3 2022 report, which came in just below our expectations on sales but significantly above our EBIT estimate.
Redeye returns with a follow-up note to Genovis’ Q2’22 report. We see a relatively weak report, although the growth in the Analytics segment (+31%) was a positive element.
Redeye provides its initial take on Genovis’ Q2’22 report, which came in below our expectations. We consider this a rather weak report from Genovis, although we note that the Analytics segment is continuing to grow solidly (+31%).